1. Home
  2. MDWD

MDWD

MediWound Ltd.

Logo MediWound Ltd.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-16-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Founded: 2000 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 151.9M IPO Year: 2014
Target Price: $32.00 AVG Volume (30 days): 67.4K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.75 EPS Growth: N/A
52 Week Low/High: $7.10 - $17.25 Next Earning Date: 05-28-2024
Revenue: $18,686,000 Revenue Growth: -29.48%
Revenue Growth (this year): 31.23% Revenue Growth (next year): 32.86%

Share on Social Networks: